Related Experiment Videos
Monoclonal antibodies in cancer therapy
G Riethmüller1, E Schneider-Gädicke, J P Johnson
1Institut für Immunologie Ludwig-Maximilians-Universität München, Germany.
Abstract:
A review of the clinical trials of antibody based cancer therapies reveals that this approach can, in rare cases, induce complete remissions in individual patients with cancer. Since these trials have usually involved patients with large tumor masses, tumor cell inaccessibility is probably a major reason for the prevailing failures. Minimal residual disease, the stage when tumor cells are few and dispersed, should therefore be a more promising target for therapeutic antibodies. This hypothesis is supported by a prospective randomized trial on patients with resected Dukes C colorectal carcinoma that resulted in increased survival and prolonged recurrence-free intervals. Thus, in addition to strategies designed to produce more effective, human-derived reagents, efforts need to be concentrated on directing passive antibody therapy towards the appropriate target.
Insights
Antibody cancer therapy shows promise for minimal residual disease, not large tumors. Targeting dispersed cancer cells with antibodies may improve patient survival and reduce recurrence.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Antibody-based cancer therapies have shown limited success, often attributed to tumor cell inaccessibility in patients with large tumor burdens.
- Complete remissions are rare, highlighting the need for refined therapeutic strategies in oncology.
Purpose of the Study:
- To evaluate the potential of therapeutic antibodies targeting minimal residual disease (MRD) in cancer.
- To investigate if targeting dispersed cancer cells offers a more effective strategy than targeting large tumors.
Main Methods:
- Reviewed clinical trials of antibody-based cancer therapies.
- Analyzed a prospective randomized trial involving patients with resected Dukes C colorectal carcinoma.
Main Results:
- Antibody therapy can induce complete remissions in rare cases, but large tumors present accessibility challenges.
- Targeting minimal residual disease (MRD) is hypothesized to be more effective.
- The prospective trial demonstrated increased survival and prolonged recurrence-free intervals in patients with colorectal carcinoma.
Conclusions:
- Minimal residual disease represents a more promising target for passive antibody therapy.
- Future efforts should focus on optimizing antibody reagents and directing therapy towards appropriate targets like MRD.
- This approach holds potential for improving outcomes in specific cancer patient populations.